Literature DB >> 1445965

Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic.

R M Post1, S R Weiss.   

Abstract

Examination of the neurobiology of psychiatric illness in general, and of affective disorders in particular, reveals a variety of associated biochemical abnormalities. These have generally been assumed to be part of the pathological process or secondary to it, and thus deserving of therapeutic efforts aimed at reversal. However, recent clinical and preclinical data suggest that some alterations occurring in the affective disorders may be compensatory and adaptive; that is, part of an endogenous therapeutic mechanism rather than part of the evolving disease process. For example, the symptom of sleep loss in depression seems to fall under this rubric inasmuch as sleep deprivation induces mood improvement in depressed patients. Preclinical data are presented that another primary pathological process--the occurrence of kindled seizures--can evoke endogenous compensatory processes that are either anticonvulsant in their own right, or enable the anticonvulsant effects of a drug such as carbamazepine. It may be that some biochemical abnormalities occurring in affective illness are similarly adaptive. As one example, increased thyrotropin-releasing hormone (TRH) has been reported in the cerebrospinal fluid (CSF) of depressed patients. This elevation of TRH and the resulting neuroendocrine profile may be part of an endogenous counter-regulatory process aimed at mood improvement. Again, preclinical seizure models are supportive in that TRH not only is induced following repeated seizures, but also exerts anticonvulsant effects on these same seizures. In an analogous fashion, TRH elevations in depressed patients may also exert ameliorating effects on depressive symptomatology. This formulation presents directly testable hypotheses that could importantly impact on our understanding of the pathophysiology of affective disorders, and suggests novel therapeutic strategies through the enhancement of endogenous compensatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445965     DOI: 10.1016/0006-3223(92)90216-m

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  Mechanisms of illness progression in the recurrent affective disorders.

Authors:  Robert M Post
Journal:  Neurotox Res       Date:  2010-11       Impact factor: 3.911

Review 2.  A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.

Authors:  R M Post; S R Weiss
Journal:  Mol Neurobiol       Date:  1996-08       Impact factor: 5.590

3.  Differences in vulnerability to nicotine-induced kindling between female and male periadolescent rats.

Authors:  Patrícia Xavier L Gomes; Gersilene V de Oliveira; Fernanda Yvelize R de Araújo; Glauce Socorro de Barros Viana; Francisca Cléa F de Sousa; Thomas N Hyphantis; Neil E Grunberg; André F Carvalho; Danielle S Macêdo
Journal:  Psychopharmacology (Berl)       Date:  2012-07-11       Impact factor: 4.530

4.  Response of carbamzepine in bipolar disorder: kindlers versus non-kindlers.

Authors:  Subhash Chandra Das; Subhash Chandra Gupta; Soumya Basu; Daya Ram
Journal:  Indian J Psychiatry       Date:  2002-07       Impact factor: 1.759

Review 5.  Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.

Authors:  Robert M Post; Susan R B Weiss
Journal:  CNS Neurosci Ther       Date:  2010-12-16       Impact factor: 5.243

Review 6.  Promising avenues of therapeutics for bipolar illness.

Authors:  Robert M Post
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.